The growth of veterinary drug compounding market is mainly driven by the increasing number of pets and growing adoption of compounded drugs to increase animal compliance with flavoring alternatives and route of administration. Currently, many drugs are approved for animal treatment. However, these are still many different species with different rare diseases conditions for which there are no FDA-approved drugs available. To overcome this issue many approved human drugs are used for the treatment of the animal with the help of drug compounding, for example, several approved chemotherapeutic drugs are used to treat cancer in dogs and cats. Moreover, the emergence of veterinary specialties such as oncology, cardiology, and neurology, and the growth of veterinary referral centers is expected to drive the need for compounded medications. The growing trend of pet adoption is expected to boost the veterinary drug compounding market. In Japan, the companion dog population has increased to approximately 12.5 million and cats have increased up to 11.6 million. Similarly, in Australia, the companion dog population has increased to 3.75 million, cats up to 2.43 million, and other animals such as birds, rodents, and fish has increased to 32.9 million other animals.